LPCN Prakiraan wutah bathi kanggo taun ngarep lipocine.com
Lipocine Inc. remains resilient to market volatility driven by demand for innovation in metabolic therapy. This chart of the consensus EPS n+1 forecast visualizes current trends, while the 11.10 metric indicates the status of expectations. Growth potential is supported by licensing payments from industry behemoths and a team of leading biochemists attracted by research autonomy and share value.
LPCN (Lipocine Inc): rincian analitis lan laporan miturut indikator
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi pasar:
- indikator kapitalisasi buku:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Lipocine Inc.|LPCN - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Lipocine Corporation|LPCN - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Lipocine Corp|LPCN - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Lipocine|Rasio cepet lipocine.com
- data bathi resik lan rasio valuasi:
LPCN - Asil keuangan resik|Bathi sing dikarepake Lipocine Inc.|LPCN - Kapitalisasi marang bathi resik|Rega marang bathi mangsa ngarep Lipocine Corporation|LPCN - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Lipocine Corp|LPCN - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Lipocine|LPCN - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan lipocine.com|LPCN - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Lipocine Inc.
- data total pendapatan lan volume dodolan:
Analisis wiwitan perusahaan:LPCN, lipocine.com
The investment attractiveness of Lipocine Inc. (LPCN) is determined by the balance between its innovative delivery technology and FDA regulatory risks. This indicator measures the expected earnings per share (EPS) dynamics, aggregating analyst forecasts for future profitability amid cost of capital volatility. By analyzing the current trajectory of next year's EPS forecasts, an investor can assess the probability of drug commercialization and the resilience of the stock price to potential approval delays.
Analisis perusahaan pesaing
ASND (Ascendis) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep Madrigal Pharmaceuticals|Prakiraan wutah bathi kanggo taun ngarep CORT|Prakiraan wutah bathi resik saben saham kanggo taun ngarep RYTM (Rhythm Pharma)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep akerotx.com AKRO|Metsera Therapeutics (MTSR) - Prakiraan wutah bathi resik saben saham ing taun ngarep|MLTX - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|CRNX: Prakiraan wutah bathi resik saben saham kanggo taun ngarep|NAMS: Prakiraan wutah bathi kanggo taun ngarep|SLNO - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Amicus Corp|89bio Pharma (ETNB) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep agios.com (AGIO)|Prakiraan wutah bathi saben saham kanggo taun ngarep structuretx.com GPCR|Prakiraan wutah bathi resik saben saham kanggo taun ngarep MiMedx Group Inc MDXG|Dinamika bathi saben saham sing diarepake ing taun ngarep RZLT|lexpharma.com - Prakiraan wutah bathi kanggo taun ngarep|MBX (MBX Biosciences Inc) - Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep|ALT: Prakiraan wutah bathi kanggo taun ngarep|Aardvark Therapeutics Inc - Dinamika bathi saben saham sing diarepake ing taun ngarep|SGMT (Sagimet Biosciences, Inc.) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep BioAge|Prakiraan wutah bathi kanggo taun ngarep BMEA|Prakiraan wutah bathi saben saham kanggo taun ngarep Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. - Prakiraan wutah bathi saben saham kanggo taun ngarep|Dinamika bathi saben saham sing diarepake ing taun ngarep VTVT|Agape ATP Corporation - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Pluri PLUR|SYBX: Prakiraan wutah bathi kanggo taun ngarep|Matinas BioPharma Holdings, Inc. - Dinamika bathi saben saham sing diarepake ing taun ngarep|SPRB (Spruce Biosciences Inc.) - Prakiraan wutah bathi kanggo taun ngarep|galecto.com (GLTO) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep organovo.com ONVO|Radius Health (RDUS) - Prakiraan wutah bathi resik saben saham ing taun ngarep
